| 0.0355 0.002 (4.72%) | 12-01 15:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.05  |
1-year : | 0.07 |
| Resists | First : | 0.04 |
Second : | 0.05 |
| Pivot price | 0.03 |
|||
| Supports | First : | 0.02 | Second : | 0.02 |
| MAs | MA(5) : | 0.03  |
MA(20) : | 0.03 |
| MA(100) : | 0.31 |
MA(250) : | 2.67 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 56.8 |
D(3) : | 50 |
| RSI | RSI(14): 26.8 |
|||
| 52-week | High : | 12.57 | Low : | 0.02 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BLPH ] has closed below upper band by 30.0%. Bollinger Bands are 96.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 111 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.04 - 0.04 | 0.04 - 0.04 |
| Low: | 0.03 - 0.03 | 0.03 - 0.03 |
| Close: | 0.03 - 0.03 | 0.03 - 0.03 |
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Mon, 20 Nov 2023
North American Morning Briefing: Stocks Futures Steady on Rates ... - Morningstar
Tue, 14 Nov 2023
Bellerophon Therapeutics: Q3 Earnings Snapshot - Times Union
Fri, 13 Oct 2023
Dow Jumps Over 200 Points; JPMorgan Earnings Top Estimates By ... - Investing.com UK
Fri, 13 Oct 2023
Bellerophon Therapeutics, Inc. Announces Resignation of Theodore ... - Marketscreener.com
Tue, 25 Jul 2023
Why Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today? - InvestorPlace
Sun, 18 Jun 2023
7 Must-Have Stocks to Buy and Hold for a Secure Future - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 45 (%) |
| Shares Short | 90 (K) |
| Shares Short P.Month | 124 (K) |
| EPS | -0.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.3 |
| Profit Margin | -164.1 % |
| Operating Margin | -195.8 % |
| Return on Assets (ttm) | -78.5 % |
| Return on Equity (ttm) | -166 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.46 |
| EBITDA (p.s.) | -0.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.11 |
| Price to Sales | 0.07 |
| Price to Cash Flow | -0.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|